TP53R175H mutation promotes breast cancer cell proliferation through CORO1A-P38 MAPK pathway regulation
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.TP53 mutations are more common in triple-negative breast cancer and linked to poorer prognosis. The TP53<sup>R175H</sup> mutation drives proliferation by affecting CORO1A and p38 signaling, with tea polyphenols showing potential therapeutic inhibition.
Area Of Science
- Oncology
- Genetics
- Molecular Biology
Background
- Breast cancer, particularly triple-negative breast cancer (TNBC), presents significant treatment challenges due to high recurrence and metastasis.
- The role of TP53 mutations in breast cancer progression, especially concerning cell proliferation, remains underexplored.
- Understanding TP53 mutation impact is crucial for improving patient outcomes.
Purpose Of The Study
- To investigate the correlation between TP53 mutations and breast cancer cell proliferation using bioinformatics and experimental approaches.
- To identify downstream targets of TP53 mutations and potential therapeutic agents.
Main Methods
- Bioinformatic analysis of TP53 mutation rates and patient prognosis.
- CCK8 assays for cell proliferation assessment.
- Western blotting for protein expression analysis (p53, p38, p-p38).
- mRNA sequencing to identify TP53 target genes.
- Molecular docking for drug discovery.
Main Results
- TP53 mutation rates are higher in TNBC, correlating with poorer patient prognosis.
- The TP53<sup>R175H</sup> mutation significantly increases breast cancer cell proliferation.
- CORO1A identified as a downstream target of TP53 mutations, promoting proliferation and downregulating p-p38.
- Molecular docking suggests tea polyphenols can inhibit proliferation via p53 binding.
Conclusions
- TP53 mutations, especially TP53<sup>R175H</sup>, are critical drivers of breast cancer proliferation and poor prognosis.
- CORO1A is a key mediator in TP53-driven proliferation.
- Tea polyphenols represent a promising therapeutic strategy for inhibiting breast cancer growth.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Three of the best-understood negative regulators are p53, p21, and retinoblastoma protein (Rb). The regulatory roles of each of these proteins were discovered after faulty copies were found in cells with uncontrolled replication (i.e.,...